New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS TrialsGlobeNewsWire • 10/20/23
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) CongressGlobeNewsWire • 10/13/23
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11GlobeNewsWire • 10/06/23
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic DermatitisGlobeNewsWire • 09/25/23
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5GlobeNewsWire • 09/19/23
Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock UpZacks Investment Research • 09/13/23
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and OlderGlobeNewsWire • 09/12/23
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)GlobeNewsWire • 09/07/23
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesPRNewsWire • 09/05/23
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) ReportGlobeNewsWire • 08/31/23
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion DealSeeking Alpha • 08/20/23
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast AsiaGlobeNewsWire • 08/10/23
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/23
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/23